It was a day of celebration for Johnson & Johnson on Tuesday after the pharmaceutical giant received approval from the U.S. Food & Drug Administration for its nasal spray antidepressant for people who are resistant to other treatments. The FDA did however put restrictions on the use of th edrug and warned that it could … Continue reading “Johnson & Johnson Gets Approval from FDA for Nasal Spray Antidepressant”
Biotech & Pharma
Biotech & Pharma
The Maker of OxyContin Explores Filing For Bankruptcy
Purdue Pharma LP, the company that makes OxyContin, is exploring bankruptcy according to sources familiar…
March 5, 2019
Biotech & Pharma
Johnson & Johnson May Soon Gain FDA Approval for Blockbuster Depression Drug
Pharmaceutical giant Johnson & Johnson could be on the cusp of gaining approval from the…
February 13, 2019
Biotech & Pharma
Bristol-Myers Has Withdrew its Application for Combination Lung Cancer Treatment
Bristol-Myers Squibb Co had a surprising announcement on Thursday as it reported financial results. The…
January 24, 2019
Biotech & Pharma
Johnson & Johnson Beats in Fourth Quarter
Johnson & Johnson reported its fourth quarter financial report ahead of the bell on Tuesday.…
January 22, 2019
Biotech & Pharma
Eli Lilly to Acquire Loxo Oncology for $8 Billion
Eli Lilly has announced that it will be acquiring Loxo Oncology for around $8 billion…
January 7, 2019
Biotech & Pharma
Pfizer to Raise the Prices of 41 Prescription Drugs in January
Despite criticism from President Trump about increasing drug prices, Pfizer will be raising its prices…
November 17, 2018
Biotech & Pharma
Novartis is Buying Endocyte for $2.1 Billion
Pharmaceutical giant Novartis is making a big purchase. The Swiss company is purchasing U.S. Endocyte…
October 18, 2018
Biotech & Pharma
This Startup Can Detect a Dangerous Blood Condition Through Heart Signals
AliveCor, a start-up medical device and artificial intelligence company that sells ECG hardware and software…
September 11, 2018
Biotech & Pharma
AstraZeneca’s Experimental Lupus Treatment Fails to Hit Primary Endpoint
Anifrolumab, AstraZeneca Plc's experimental treatment for lupus, has missed its primary endpoint in a study.…
September 3, 2018
Biotech & Pharma
Insys Therapeutics Skyrockets on FDA Fast Track Designation
Shares of Insys Therapeutics were on the rise in Thursday's trading session after the company…
August 30, 2018
Biotech & Pharma
Gilead Paid $510 Million For This Drug But Sold it For Only $3 Million
It was five years ago that Gilead Sciences Inc. paid $510 million for a deal…
August 23, 2018
Biotech & Pharma
PTC Therapeutics Announces it Will Buy Agilis Biotherapeutics for $200M
It was on Thursday that PTC Therapeutics announced that it plans to acquire five-year old…
July 20, 2018
Biotech & Pharma
Sage Shares Soar After FDA Gives Green Light for This
Shares of Sage Therapeutics were exploding in Tuesday trading after the Food and Drug Administration…
June 12, 2018